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Proof-of-Concept Studies of Interferon-free
Regimens
With more than 30 direct-acting antiviral agents (DAAs)
in clinical trials, the hepatitis C community (scientists,
physicians, patients) expect that the right combinations of
DAAs will emerge, permitting treatment of hepatitis C virus
(HCV) genotype 1 with interferon (IFN)-free regimens. In
2012, the first report of sustained virologic response (SVR)
with an IFN-free regimen in patients with genotype 1 was
published. In this study, 4 of 11 (36%; 2 of 9 with geno-
type 1a, 2 of 2 with genotype 1b) noncirrhotic null res-
ponders to pegylated IFN (PEG-IFN) and ribavirin (RBV)
achieved SVR after a 24-week course of asunaprevir, a pro-
tease inhibitor, and daclatasvir, a NS5A inhibitor.1 Whereas
the number of patients studied was small and the SVR rate
was low in patients with genotype 1a, these data provided
proof of concept that SVR can be achieved without IFN or
RBV in patients with HCV genotype 1. These data have
encouraged the evaluation of many other IFN-free regimens.
IFN-free Regimens Expected to Be
Approved in 2014/2015
In late 2013, two new DAAs for genotype 1 were
approved by the US Food and Drug Administration (FDA):
simeprevir, a protease inhibitor, and sofosbuvir, a nucleotide
polymerase inhibitor. Both drugs are to be used with PEG-
IFN and RBV. Although sofosbuvir was also approved to be
used with RBV (without PEG-IFN) for IFN-ineligible
patients, the SVR rate of the 2-drug regimen is substantially
lower than the 3-drug regimen: 68% to 76% versus 89%.2-4
Many experts have advocated the off-label combination of
simeprevir and sofosbuvir based on data from a phase 2
study, and this approach is endorsed by the American Asso-
ciation for the Study of Liver Diseases and the Infectious
Diseases Society of America HCV guidelines.5 However,
only 167 patients were included in that study, and the cost
of this off-label combination is substantially higher than the
approved regimens.
Two IFN-free regimens for HCV genotype 1 are expected
to be approved by the FDA in late 2014. Phase 3 trials of
both regimens have been completed and results published.
The ION-1, 2, and 3 trials compared sofosbuvir plus ledi-
pasvir, an NS5A inhibitor coformulated as a single pill, with
or without RBV, for 8 to 24 weeks (Table 1) (Fig. 1). In the
ION-1 trial in treatment-na€ıve patients (16% with cirrhosis),
SVR rates after 12 weeks of therapy were 97% and 98% in
the groups with or without RBV, respectively7; results in the
24-week treatment groups were 99% and 98% with and
without ribavirin respectively.7 In the ION-3 trial, the possi-
bility of shortening the duration of treatment to 8 weeks
was tested in treatment-na€ıve patients with no to moderate
fibrosis (Metavir F0-F2); SVR rates after 8 weeks of therapy
were 93% and 94% in the groups with or without RBV,
respectively, and 95% after 12 weeks of treatment without
RBV.6 In the ION-2 trial in treatment-experienced patients
(20% with cirrhosis), SVR rates after 12 weeks of therapy
were 96% and 94% in the groups with or without RBV,
respectively, and 99% in patients who received 24 weeks of
treatment, with or without RBV.8 Anemia was reported in
0.5% of patients in the RBV-free groups compared to 9.2%
in the RBV-containing groups. Fewer than 1% of patients in
the ION studies discontinued treatment due to treatment-
related adverse events.
The AbbVie regimen consisted of fixed-dose combination
of ABT-450 (a protease inhibitor) with ritonavir boost cofor-
mulated with ombitasvir (ABT-267, an NS5A inhibitor) plus
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dasabuvir (ABT-333, a non-nucleoside polymerase inhibitor)
with or without RBV for 12 or 24 weeks (Table 2).9-12
SAPPHIRE-I, PEARL-III, and PEARL-IV included treatment
na€ıve, noncirrhotic patients; and SAPPHIRE-II and PEARL-II
included treatment-experienced, noncirrhotic patients,
whereas TURQUOISE-II included both treatment-na€ıve and
treatment-experienced patients with compensated cirrhosis.
In SAPPHIRE-I, all patients received 12 weeks treatment with
RBV, and SVR rates were 95% for subtype 1a and 98% for sub-
type 1b (Fig. 2a).11 In PEARL-III and PEARL-IV, all patients
received 12 weeks treatment with or without RBV; SVR rates
for PEARL-III (subtype 1b) were 99% in both groups; and for
PEARL-IV (subtype 1a) rates were 97% and 90% in the groups
with and without RBV, respectively (Fig. 2a). In SAPPHIRE-II,
49% of the patients were null responders to PEG-IFN and
RBV. All patients received 12 weeks treatment with RBV, and
SVR rates were 96% for subtype 1a and 97% for subtype 1b
(Fig. 2b).12 In PEARL-II, all patients had subtype 1b, and SVR
rates were 97% and 100% in the groups with and without
RBV, respectively (Fig. 2b). In TURQUOISE-II, all patients
had cirrhosis and all received RBV. SVR rates were 92% and
96% for the groups that received 12 and 24 weeks treatment,
respectively (Fig. 2c).9 Only 2% of the patients in either treat-
ment group in TURQUOISE-II discontinued treatment
because of adverse events.
Other IFN-free Regimens in the Pipeline
There are several other IFN-free regimens in the pipeline.
The furthest along involves a combination of asunaprevir,
daclatasvir, and BMS-791325—a nonnucleoside polymerase
inhibitor. In a phase 2b trial of 166 treatment-na€ıve patients
including 9% with cirrhosis, SVR rates were 92% and 92%
TABLE 1 SVR Rates in Phase 3 Trials of Sofosbuvir-based Regimens in Patients with HCV Genotype 1 (see references 6-8)
Study Population Treatment Duration SVR12 Rates
ION-1 GT 1 treatment-na€ıve, including 15.7 percent (136/865) with cirrhosis SOF/LDV 12 weeks 97.7% (209/214)
SOF/LDV1RBV 12 weeks 97.2% (211/217)
SOF/LDV 24 weeks NA (n5217)
SOF/LDV1RBV 24 weeks NA (n5217)
ION-2 GT 1 treatment-experienced, including 20.0 percent (88/440) with cirrhosis SOF/LDV 12 weeks 93.6% (102/109)
SOF/LDV1RBV 12 weeks 96.4% (107/111)
SOF/LDV 24 weeks 99.1% (108/109)
SOF/LDV1RBV 24 weeks 99.1% (110/111)
ION-3 GT 1 treatment-na€ıve SOF/LDV 8 weeks 94.0% (202/215)
SOF/LDV1RBV 8 weeks 93.1% (201/216)
SOF/LDV 12 weeks 95.4% (206/216)
SOF 400 mg once daily and LDV 90 mg once daily coformulated as a single pill; RBV weight-based dosing twice daily.
Abbreviations: GT, genotype; LDV, ledipasvir; SOF, sofosbuvir.
Figure 1 SVR12 rates in ION-I, ION-II, and ION-III trials of sofosbuvir and
ledipasvir with or without ribavirin in treatment-na€ıve and treatment-
experienced patients with HCV genotype 1.
TABLE 2 SVR Rates to Phase 3 Trials of IFN-free AbbVie Regimens in Patients with HCV Genotype 1(see references 9-12)
Study (duration) Patients Treatment Regimen SVR12
PEARL-II (12 weeks) GT1b treatment-experienced AbbVie regimen1RBV (n5 88) 97%
AbbVie regimen only (n591) 100%
PEARL-III (12 weeks) GT1b treatment- na€ıve AbbVie regimen1RBV (n5 210) 99%
AbbVie regimen only (n5209) 99%
PEARL-IV (12 weeks) GT1a treatment- na€ıve AbbVie regimen1RBV (n5 100) 97%
AbbVie regimen only (n5205) 90%
TURQUOISE-II (12 and 24 weeks) GT1 treatment- na€ıve and treatment-experienced
with compensated cirrhosis
AbbVie regimen1RBV, 12 weeks (n5 208) 92%
AbbVie regimen1RBV, 24 weeks (n5 172) 96%
SAPPHIRE-I (12 weeks) GT1 treatment- na€ıve AbbVie regimen1RBV (n5 473) 96%
SAPPHIRE-II (12 weeks) GT1 treatment-experienced AbbVie regimen1RBV (n5 297) 96%
AbbVie regimen consists of ABT-450/ritonavir (150 mg/100 mg) coformulated with Ombitasvir (ABT-267) (25 mg), dosed once daily, and Dasabuvir
(ABT-333) (250 mg), dosed twice daily. RBV weight-based dosing, twice daily.
Abbreviation: GT, genotype.
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in the groups that received low-dose or high-dose BMS-
791325.13 Phase 3 trial of this regimen is ongoing. Combi-
nation of daclatasvir and asunaprevir without BMS-791325
is also pursued in Japan, where nearly all patients with
HCV genotype 1 have subtype 1b. As discussed earlier, this
combination has low efficacy for subtype 1a. Another regi-
men involves a combination of a second-generation protease
inhibitor MK-5172 and a second-generation NS5A inhibitor
MK-8742.14 Preliminary data showed SVR rates of 96% to
100% with or without RBV.
Are We Ready to Say Good-bye to Interferon
for HCV Genotype 1?
Data from the studies presented above show that a 12-
week course of IFN-free, all-oral combination of 2 or 3
DAAs can result in> 90% SVR rates in most patients
with genotype 1 infection, including those with subtype
1a, treatment-experienced patients, and patients with cir-
rhosis. Some of these regimens would also be RBV-free.
Phase 3 trials of two of the IFN-free regimens have been
completed and qualify for expedited review by the FDA;
thus, it is expected that they will be available in late
2014 or early 2015. This is tremendous news for
patients and HCV providers because the wait is finally
over for most, if not all, patients with genotype 1
infection.n
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